Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Bertrand Cariou, Moshe Phillip et al.|The Lancet Diabetes & Endocrinology|2017

Cited by 295